Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of transdermal buprenorphine (Transtec) as first-line WHO step 3 opioid for medium- to long-term cancer pain
2005-003703-36Phase 4Terminated
- Sponsor
- ASST Fatebenefratelli Sacco
- Start
- Feb 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of buprenorphine in cancer pain, sponsored by ASST Fatebenefratelli Sacco. Started Feb 2007; status: terminated.
02
Drugs
buprenorphine
03
Conditions
cancer pain
Beyond the preview
Go deeper on 2005-003703-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003703-36.